Mediwound Ltd. (MDWD) — 6-K Filings

6-K Filings (25)

• MediWound Ltd. Files 6-K Report — Apr 2, 2026 Risk: low
  MediWound Ltd. filed a 6-K report on April 2, 2026, detailing its status as a foreign issuer. The filing includes standard report documents and exhibits, with i
• MediWound Reports Q3 2025 Financials and Corporate Update — Nov 20, 2025 Risk: low
  MediWound Ltd. reported its third quarter 2025 financial results and provided a corporate update on November 20, 2025. The company issued a press release detail
• MediWound Ltd. Files 6-K for Share Offering — Sep 30, 2025 Risk: medium
  On September 29, 2025, MediWound Ltd. entered into a securities purchase agreement for an offering of 1,734,105 ordinary shares. The filing does not specify the
• MediWound Ltd. Raises $30 Million in Direct Offering — Sep 29, 2025 Risk: medium
  On September 29, 2025, MediWound Ltd. announced a registered direct offering to raise $30 million through the sale of ordinary shares. The company is based in Y
• MediWound Execs Buy Shares — Aug 19, 2025 Risk: low
  On August 18, 2025, MediWound Ltd. reported that its Chairman, Nachum (Homi) Shamir, and CEO, Ofer Gonen, each bought ordinary shares in the company. The total
• MediWound Ltd. Reports Q2 2025 Financial Results — Aug 14, 2025 Risk: low
  MediWound Ltd. reported its financial results for the second quarter and six months ended June 30, 2025, on August 14, 2025. The filing provides details on the
• MediWound Ltd. Reports Q1 2025 Financials and Update — May 21, 2025 Risk: low
  MediWound Ltd. announced its first quarter 2025 financial results and provided a corporate update on May 21, 2025. The company is a foreign private issuer filin
• MediWound Ltd. Holds 2025 Annual Shareholder Meeting — May 15, 2025 Risk: low
  MediWound Ltd. held its 2025 Annual General Meeting of Shareholders on May 15, 2025. Shareholders voted on several proposals that were previously detailed in th
• MediWound Ltd. Schedules 2025 AGM, Files Proxy Materials — Apr 7, 2025 Risk: low
  MediWound Ltd. filed a Form 6-K on April 7, 2025, to report proxy materials for its 2025 Annual General Meeting of Shareholders. The meeting is scheduled for Ma
• MediWound Ltd. Files Form 6-K for February 2025 — Feb 12, 2025 Risk: low
  On February 12, 2025, MediWound Ltd. announced the issuance of a press release. The press release is titled "MediWound I". This filing is a Form 6-K, which is a
• MediWound Ltd. Updates on Commercial Production — Jan 8, 2025 Risk: low
  On January 8, 2025, MediWound Ltd. published a presentation on its website. This presentation highlighted the company's commercial production activities and pro
• MediWound Ltd. Holds Special Shareholder Meeting — Dec 19, 2024 Risk: low
  MediWound Ltd. held a special general meeting of shareholders on December 19, 2024. The primary agenda item was a single proposal, detailed in their notice and
• MediWound Ltd. Reports Share Acquisitions in 6-K Filing — Dec 16, 2024 Risk: low
  MediWound Ltd. (the "Company") filed a Form 6-K on December 16, 2024, to report recent open market acquisitions of its ordinary shares. The filing indicates the
• MediWound Ltd. Issues Press Release — Nov 26, 2024 Risk: low
  On November 26, 2024, MediWound Ltd. announced the issuance of a press release. The press release is titled "Med". Further details regarding the content of the
• MediWound Ltd. Files 6-K for Shareholder Meeting — Nov 14, 2024 Risk: low
  MediWound Ltd. is filing a Form 6-K on November 14, 2024, to report proxy materials for an Extraordinary General Meeting of Shareholders. The filing is made pur
• MediWound Appoints New CEO, Reports Q2 Financials — Aug 15, 2024 Risk: medium
  On August 15, 2024, MediWound Ltd. announced the appointment of Dr. Gili Harir as its new Chief Executive Officer, effective immediately. Dr. Harir, who previou
• MediWound Ltd. Reports Q2 2024 Financial Results — Aug 14, 2024 Risk: low
  MediWound Ltd. reported its financial results for the quarter and six months ended June 30, 2024, on August 14, 2024. The filing details the company's operation
• MediWound Ltd. Files 6-K Report — Aug 5, 2024 Risk: low
  MediWound Ltd. filed a Form 6-K on August 5, 2024, reporting as a foreign private issuer. The filing indicates the company is subject to the reporting requireme
• MediWound Ltd. Completes Merger with 03 Life Sciences — Jul 16, 2024 Risk: low
  On July 16, 2024, MediWound Ltd. announced the closing of its previously disclosed merger agreement with 03 Life Sciences. The transaction was approved by MediW
• MediWound Ltd. Announces Private Placement of Ordinary Shares — Jul 15, 2024 Risk: medium
  On July 15, 2024, MediWound Ltd. entered into a share purchase agreement for a private placement of ordinary shares with unnamed purchasers. The filing does not
• MediWound Ltd. Holds 2024 Annual Shareholder Meeting — Jul 9, 2024 Risk: low
  MediWound Ltd. held its 2024 annual general meeting on July 9, 2024. The filing does not specify the outcomes or resolutions of this meeting, only that it occur
• MediWound Ltd. Files May 2024 Report on Form 6-K — May 29, 2024 Risk: low
  MediWound Ltd. filed a Form 6-K on May 29, 2024, reporting on its activities for the month of May 2024. The company, incorporated in Israel, is a foreign privat
• MediWound's EscharEx® Beats SANTYL® in ChronEx Phase II Study — Feb 12, 2024 Risk: low
  On February 12, 2024, MediWound Ltd. announced positive results from its ChronEx Phase II study, comparing its product EscharEx® head-to-head against SANTYL®. T
• MediWound: FDA Accepts NexoBrid Pediatric Burn Application — Jan 9, 2024
  MediWound Ltd. announced on January 9, 2024, that the FDA has accepted for review its supplemental Biologics License Application (BLA) for NexoBrid. This BLA ai
• MediWound Presents at J.P. Morgan Healthcare Conference — Jan 8, 2024
  MediWound Ltd. presented at the J.P. Morgan 42nd Annual Healthcare Conference on January 8, 2024, showcasing its commercial and clinical products, along with fu

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX